» Articles » PMID: 30304505

Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): An Overview and Lessons Learned

Overview
Journal J Infect Dis
Date 2018 Oct 11
PMID 30304505
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP), a multiphase surveillance study characterizing the burden of disease in South Asia, was to inform data collection for prospective surveillance and to capture clinical aspects of disease.

Methods: Through a retrospective record review conducted at hospitals in Bangladesh, India, Nepal, and Pakistan, we examined laboratory and clinical records to assess the culture positivity rate for Salmonella Typhi and Salmonella Paratyphi, age and sex distribution, and antimicrobial susceptability in each country.

Results: Of all blood cultures performed in Bangladesh, India, Nepal, and Pakistan, 1.5%, 0.43%, 2%, and 1.49%, respectively, were positive for S. Typhi and 0.24%, 0.1%, 0.5%, and 0.67%, respectively, were positive for S. Paratyphi. A higher proportion of laboratory-confirmed infections in Bangladesh and Pakistan were aged ≤5 years, while India and Nepal had a higher proportion of participants aged 15-25 years. In all countries, the sex of the majority of participants was male. The majority of isolates in all countries were resistant to fluoroquinolones, with a high proportion also resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole.

Discussion: Enteric fever remains endemic in South Asia. Data generated by this study can help inform strategies for implementation and evaluation of prevention and control measures.

Citing Articles

Estimating the subnational prevalence of antimicrobial resistant Salmonella enterica serovars Typhi and Paratyphi A infections in 75 endemic countries, 1990-2019: a modelling study.

Lancet Glob Health. 2024; 12(3):e406-e418.

PMID: 38365414 PMC: 10882211. DOI: 10.1016/S2214-109X(23)00585-5.


Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.

Tamrakar D, Poudel P, Thapa P, Singh S, Khadgi A, Thapa S Hum Vaccin Immunother. 2024; 20(1):2301631.

PMID: 38189360 PMC: 10793708. DOI: 10.1080/21645515.2023.2301631.


Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014-2018.

Jayaprasad N, Borhade P, LeBoa C, Date K, Joshi S, Shimpi R Am J Trop Med Hyg. 2023; 109(3):571-574.

PMID: 37549903 PMC: 10484249. DOI: 10.4269/ajtmh.23-0102.


Dynamic Incidence of Typhoid Fever over a 10-Year Period (2010-2019) in Kibera, an Urban Informal Settlement in Nairobi, Kenya.

Ngeno E, Lind M, Audi A, Ouma A, Oduor C, Munywoki P Am J Trop Med Hyg. 2023; 109(1):22-31.

PMID: 37253442 PMC: 10324018. DOI: 10.4269/ajtmh.22-0736.


Paratype: a genotyping tool for Salmonella Paratyphi A reveals its global genomic diversity.

Tanmoy A, Hooda Y, Sajib M, da Silva K, Iqbal J, Qamar F Nat Commun. 2022; 13(1):7912.

PMID: 36564386 PMC: 9782287. DOI: 10.1038/s41467-022-35587-6.


References
1.
Antillon M, Saad N, Baker S, Pollard A, Pitzer V . The Relationship Between Blood Sample Volume and Diagnostic Sensitivity of Blood Culture for Typhoid and Paratyphoid Fever: A Systematic Review and Meta-Analysis. J Infect Dis. 2018; 218(suppl_4):S255-S267. PMC: 6226661. DOI: 10.1093/infdis/jiy471. View

2.
Qamar F, Yousafzai M, Sultana S, Baig A, Shakoor S, Hirani F . A Retrospective Study of Laboratory-Based Enteric Fever Surveillance, Pakistan, 2012-2014. J Infect Dis. 2018; 218(suppl_4):S201-S205. PMC: 6226712. DOI: 10.1093/infdis/jiy205. View

3.
Voysey M, Pollard A . Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Clin Infect Dis. 2018; 67(1):18-24. DOI: 10.1093/cid/cix1145. View

4.
Mai N, Phan V, Vo A, Tran C, Lin F, Bryla D . Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med. 2003; 349(14):1390-1. DOI: 10.1056/NEJM200310023491423. View

5.
Jin C, Gibani M, Moore M, Juel H, Jones E, Meiring J . Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017; 390(10111):2472-2480. PMC: 5720597. DOI: 10.1016/S0140-6736(17)32149-9. View